Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.1052W HIGH $7.98
Volume
56.58 K
Value Traded
2.12 M
Short % Float
2.21%
-6.74%Week
-25.39%1 Month
-22.79%3 Month
-36.88%6 Month
-65.86%5 Year
-66.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
685.54 M
EPS (TTM)
-2.84
P/E Ratio
-
Ent. Value
1.01 B
Total Shares
208.92 M
Float Shares
219.95 M
Insiders
7.56%
Institutions
29.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Inventiva S.A. - American Depository Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inventiva S.A. - American Depository Shares
117Total events
14Upcoming
19Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationLanifibranorPresentation
Five lanifibranor abstracts to be presented as posters at Paris MASH Meeting
MASHsource ↗
▲Last Patient Last VisitLanifibranorTrial
Last patient completed final 72-week visit in NATiV3 Phase 3 trial
MASH with moderate and advanced fibrosissource ↗
▼Runway Guidance UpdateCorporate
Cash runway guidance: financing until end of Q3 2026 prior to offering
◆Equity OfferingCorporate
General meeting of shareholders to approve issuance of New EIB Warrants
◆Management ChangeCorporate
Barbara Krebs-Pohl, Anne Prener, and Camilla Soenderby appointed as independent Board members
●Oral PresentationPresentation
Portzamparc BNP Paribas group mid & small caps conference 2026, Paris
▲Debt Royalty FinancingCorporate
Repaid EIB Loans in full (€62M) and repurchased portion of EIB Warrants (€50M)
◆Oral PresentationPresentation
Inventiva presentation at 2026 Jefferies Global Healthcare Conference
MASHsource ↗
▼Equity OfferingCorporate
Offering of 27,272,727 American Depositary Shares for €103.0 million
◆Poster PresentationLanifibranorPresentation
Poster presentation SAT-117-YI at EASL Congress 2026
MASHsource ↗
◆Poster PresentationLanifibranorPresentation
Poster presentation FRI-189 at EASL Congress 2026
MASHsource ↗
▲Management ChangeCorporate
Appointment of Axel-Sven Malkomes as CFO, Susan Coles as Legal Director, and Pamela Herbster as HR Director
●Quarterly UpdateCorporate
Filing of 2025 Universal Registration Document and Annual Report on Form 20-F
●Quarterly UpdateCorporate
Conference call to discuss 2025 financial results and business update
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference fireside chat
●Runway Guidance UpdateCorporate
Cash runway guidance: operations funded until mid Q1 2027; with Tranche 3 warrants until mid Q3 2027
◆Oral PresentationPresentation
CEO Andrew Obenshain fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Oral PresentationPresentation
Inventiva presentation at 44th Annual J.P. Morgan Healthcare Conference
▼Equity OfferingCorporate
Temporary suspension of ordinary shares trading on Euronext Paris due to U.S. public offering of ADSs
▼Equity OfferingCorporate
Closed public offering in the United States for gross proceeds of $172.5 million
◆Management ChangeCorporate
Appointment of new CEO Andrew Obenshain effective October 1, 2025
●Management ChangeCorporate
Appointment of Martine Zimmermann as EVP Regulatory Affairs and Quality Assurance
Past FDA Catalysts and PDUFA Decisions
How IVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-10 | lanifibranor | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$240M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 658)
Percentile Rank
Inventiva S.A. - American Depository Shares carries a moderate pipeline score (44/100), with $842M risk-adjusted pipeline value, led by Lanifibranor in Nonalcoholic Fatty Liver Disease (NAFLD) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lanifibranor Small moleculeCompletedNCT03459079 | Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | COMPLETED | 128 | Jun 1, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every IVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lanifibranor BreakthroughFast Track | MASH | Phase 1/2 | 2026-09-08 | improvements in metabolic profile and cardiovascular risk factors; increases in adiponectin; improvements observed in measures of insulin sensitivity, glycemic control, lipid parameters, and selected cardiovascular risk factorsRead More | Inventiva to Present Multiple Abstracts at Paris MASH 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 2 % (-28.6 %) | 23.87 M | 6.31 M | 21.56% ( 1.12 M) |
IVA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IVA ranks across every disease it competes in
Competitive Position is a premium feature
See how IVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIVA News
IVA▼ -1.4%today
Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026
Inventiva announced the presentation of three scientific abstracts at the AASLD The Liver Meeting 2026, focusing on the effects of lanifibranor in treating metabolic dysfunction-associated steatoh hepatitis (MASH). The data highlights the drug's ability to activate multiple PPAR isoforms, demonstrating improvements in endothelial cell alterations and vascular anomalies. Lanifibranor is currently under evaluation in a Phase 3 study, with primary results expected in Q4 2026.
Read more →IVA▼ -1.4%today
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Inventiva announced the presentation of three scientific abstracts at AASLD The Liver Meeting 2026, focusing on lanifibranor's effects on metabolic dysfunction-associated steatohepatitis (MASH). The data highlights the drug's ability to activate multiple PPAR isoforms, showing improvements in liver conditions. Lanifibranor is currently in Phase 3 trials, with results expected soon.
Read more →IVAInventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Inventiva reported its financial results for the first half of 2026, noting no revenues and a net loss of €69.5 million. The company maintains a cash position of €166.1 million and expects topline results from its Phase 3 NATiV3 trial by Q4 2026. Management will discuss these results in a webcast on September 28, 2026.
Read more →IVAInventiva to Present Multiple Abstracts at Paris MASH 2026
Inventiva announced the presentation of five abstracts at the Paris MASH Meeting, showcasing Phase 1 and Phase 2 clinical data on lanifibranor, which demonstrated improvements in metabolic profiles and cardiovascular risk factors in patients with MASH. The drug is currently in Phase 3 trials, with topline results expected soon. Lanifibranor is the only pan-PPAR agonist in clinical development for MASH.
Read more →IVAInventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026
Inventiva announced the presentation of five abstracts at the Paris MASH Meeting, showcasing clinical Phase 1 and Phase 2 data for lanifibranor, which demonstrates improvements in metabolic profiles and cardiovascular risk factors in patients with MASH. The drug is currently being evaluated in a Phase 3 clinical study, with primary results expected in Q4 2026. The company aims to characterize the pharmacological profile of lanifibranor further.
Read more →IVAInventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Inventiva has announced the completion of the last patient visit in the NATiV3 Phase 3 clinical trial for lanifibranor, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The trial enrolled over 1,000 patients, and topline results are anticipated in Q4 2026. If results are favorable, a regulatory submission is planned for H1 2027, with a potential U.S. launch in 2028.
Read more →IVAInventiva Appoints Chris Benecchi as Chief Operating Officer
Inventiva has appointed Chris Benecchi as Chief Operating Officer to enhance operational readiness as the company approaches pivotal Phase 3 results for lanifibranor in treating MASH. With a potential U.S. launch in 2028, Inventiva is building its infrastructure and capabilities for commercialization. Benecchi brings extensive experience in biopharmaceutical leadership and launch strategies.
Read more →IVAInventiva nomme Chris Benecchi au poste de Chief Operating Officer
Inventiva has appointed Chris Benecchi as Chief Operating Officer to lead operational preparations for the Phase 3 NATiV3 study of lanifibranor, targeting metabolic dysfunction-related steatohepatitis (MASH). His extensive biopharma experience is expected to enhance the company's readiness for a potential U.S. launch in 2028, pending regulatory approval. The company aims to support sustainable adoption of the treatment.
Read more →IVACorrection: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Inventiva has corrected its preliminary financial results for the first half of 2026, revealing cash reserves of €166.1 million. The company reported no revenues during this period, while net cash used in operating activities was €48.7 million. Despite a positive cash flow from investing activities, Inventiva's current cash is not sufficient to cover its operating needs for the next year.
Read more →IVAInventiva Announces Preliminary Financial Results for the First Half of 2026¹
Inventiva reported preliminary financial results for the first half of 2026, showing a cash position of €166.1 million. The company recorded no revenues during this period, a decline from €4.5 million in 2025. Despite a significant increase in cash generated from investing activities, the net cash used in operations remains high, and the company anticipates needing additional financing to sustain operations beyond the next year.
Read more →IVA▼ -5.1%on this news
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Inventiva has successfully completed the restructuring of EIB warrants, issuing approximately 15.7 million new warrants to the European Investment Bank. This move is part of a broader refinancing strategy aimed at optimizing the company's capital structure. The new warrants replace older ones, eliminating specific anti-dilution protections and enhancing financial flexibility for the development of lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis.
Read more →IVAResults of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
Inventiva announced the results of its Combined Shareholders' Meeting held on June 30, 2026. All proposed resolutions were adopted except for one, which was negatively recommended by the Board. The meeting also approved the compensation policy for corporate officers. Inventiva continues its focus on developing an oral therapy for MASH.
Read more →IVAInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Inventiva has successfully repaid its existing EIB loans amounting to approximately €62 million and repurchased a portion of EIB warrants for €50 million. Additionally, the company issued the first two tranches of a new debt financing transaction, raising €75 million. These actions are part of a broader strategy to enhance its financial stability and support its clinical development efforts.
Read more →IVATranslation for information purpose only INVENTIVA French soci t Anonyme with a Board of Directors with a share capital of EUR 2,090,074.75 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies
INVENTIVA is scheduled to hold its ordinary and extraordinary general meeting on June 30, 2026, in Paris. The meeting will address various resolutions, including the approval of the financial statements that disclose a net accounting loss of EUR 207,965,630.56 for the year ending December 31, 2025. Additionally, resolutions will focus on the approval of a subscription agreement with Samsara BioCapital L.P. and discussions on executive compensation. These developments reflect the company's ongoing financial challenges.
Read more →IVACopyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time
Inventiva S.A. is set to hold a Joint Ordinary & Extraordinary General Meeting of Shareholders, where shareholders will vote on several proposals. Significant decisions include the issuance of share subscription warrants and the delegation of authority to the Board of Directors regarding share capital increases. The meeting will also address corporate governance, such as the approval of compensation policies for directors. This marks a critical step in aligning the company’s articles of association with current laws and regulations.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Inventiva has announced the resumption of trading for its ordinary shares on Euronext Paris, effective from 3:30 p.m. CEST on June 2, 2026. The trading halt was initiated at the company's request due to a Debt Financing Transaction and the offering of American Depositary Shares. Inventiva is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a Phase 3 clinical trial.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Inventiva has announced a comprehensive capital structure optimization involving €130 million in new debt financing and a $120 million equity offering. This strategy aims to simplify its capital structure by repurchasing existing warrants and extending its cash runway into early 2028. The company reiterated its confidence in achieving a Phase 3 readout for lanifibranor in Q4 2026, followed by a potential regulatory filing in H1 2027.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Inventiva has announced a temporary halt in trading of its ordinary shares on Euronext Paris, effective from 9:00 a.m. CEST. This decision was made at the company's request in anticipation of a forthcoming financing transaction. Trading is expected to resume later today at approximately 3:30 p.m. CEST, coinciding with the expected start of trading on the Nasdaq Global Market.
Read more →IVAInventiva Reports 2026 First Quarter Financial Information¹
Inventiva reported its financial results for Q1 2026, showing cash and cash equivalents of €75 million. The company did not generate any revenue during this period, similar to Q1 2025. Looking ahead, Inventiva anticipates key milestones, including topline results from its NATiV3 trial in late 2026. However, uncertainties regarding future funding and ongoing losses remain.
Read more →IVAInventiva to Present at 2026 Jefferies Global Healthcare Conference
Inventiva, a clinical-stage biopharmaceutical company, announced that its CEO, Andrew Obenshain, will present at the 2026 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for June 3, 2026, and will focus on the company's development of therapies for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, Inventiva leadership will hold one-on-one meetings during the conference.
Read more →About Inventiva S.A. - American Depository Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next IVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime